Benefit and danger from immunotherapy in myasthenia gravis

In the last years, significant advances have improved the knowledge of myasthenia gravis (MG) immunopathogenesis and have enabled to realize new molecules with a selective action targeting compounds of the immunological system. This review discusses emerging treatments for MG, including complement i...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodolico, Carmelo, Nicocia, Giulia, Damato, Valentina, Antonini, Giovanni, Liguori, Rocco, Evoli, Amelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7861968/
https://www.ncbi.nlm.nih.gov/pubmed/33543421
http://dx.doi.org/10.1007/s10072-021-05077-6
Descripción
Sumario:In the last years, significant advances have improved the knowledge of myasthenia gravis (MG) immunopathogenesis and have enabled to realize new molecules with a selective action targeting compounds of the immunological system. This review discusses emerging treatments for MG, including complement inhibitors, neonatal Fc receptor targeting agents, and B cell interfering drugs, focusing on benefit and danger. In the second section of the review, several related adverse events of immunotherapy, including MGonset, are debated.

Ejemplares similares